Receptos Inc (RCPT) 104.00 $RCPT
Receptos posts 3Q loss
Automated Insights - Tue Nov 04, 7:19AM CST
SAN DIEGO (AP) _ Receptos Inc. (RCPT) on Tuesday reported a loss of $32.2 million in its third quarter.
RCPT: 104.00 (+0.69)
Receptos Provides Development Updates and Reports Third Quarter 2014 Financial Results
GlobeNewswire - Tue Nov 04, 6:00AM CST
- Recent positive Phase 2 induction results for TOUCHSTONE trial of RPC1063 in ulcerative colitis (UC) support initiation of broad program in inflammatory bowel disease -
RCPT: 104.00 (+0.69)
Receptos to Present at Nomura BioPharma Conference
GlobeNewswire - Mon Nov 03, 3:01PM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that Faheem Hasnain, its President and Chief Executive Officer, will be presenting at the Nomura BioPharma Conference at the Mandarin Oriental Hotel in Boston. The presentation is scheduled for Thursday, November 6 at 2:15pm Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's website at www.receptos.com. A replay will be available for 14 days after the event.
RCPT: 104.00 (+0.69)
Clinical Trial Results, Product Approval Letter, Financial Results, and Upcoming Event - Research Reports on Receptos, Wright, United Therapeutics, Abbott and CareFusion
PR Newswire - Fri Oct 31, 7:40AM CDT
Today, Analysts Review released its research reports regarding Receptos Inc. (NASDAQ: RCPT), Wright Medical Group Inc. (NASDAQ: WMGI), United Therapeutics Corporation (NASDAQ: UTHR), Abbott Laboratories (NYSE: ABT) and CareFusion Corporation (NYSE: CFN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7594-100free.
ABT: 43.61 (+0.32), WMGI: 29.96 (-0.65), CFN: 57.38 (+0.13), UTHR: 124.81 (-5.61), RCPT: 104.00 (+0.69), WMGIZ: 4.40 (+0.20)
Receptos to Hold Third Quarter 2014 Financial Results Conference Call and Webcast
GlobeNewswire - Wed Oct 29, 3:12PM CDT
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, will announce financial results for the third quarter ended September 30, 2014 on Tuesday, November 4 before the markets open. The announcement will be followed by a live webcast and conference call at 8:00 a.m. Eastern time (5:00 a.m. Pacific time).
RCPT: 104.00 (+0.69)
Receptos (RCPT) Worth Watching: Stock Moves Up 41.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 8:39AM CDT
Receptos, Inc. (RCPT) was a big mover last session, as its shares rose over 41% on the day.
LCI: 56.25 (-1.27), PTLA: 27.89 (-0.29), RCPT: 104.00 (+0.69), IG: 9.95 (-0.10)
Nasdaq stocks posting largest percentage increases
AP - Tue Oct 28, 5:14PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
VDSI: 25.80 (+0.32), ECHO: 26.91 (+0.69), LAYN: 7.37 (+0.17), NVAX: 5.55 (+0.03), SCYX: 8.60 (-0.13), RCPT: 104.00 (+0.69), TRNX: 26.34 (-0.56), IDTI: 16.51 (+0.02), SANM: 25.22 (+0.10)
Twitter and Amgen are big market movers
AP - Tue Oct 28, 3:42PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
AMKR: 6.32 (-0.21), KSS: 55.17 (+0.22), MU: 33.37 (-0.14), PFE: 30.28 (+0.09), HAL: 51.18 (-2.70), AMGN: 160.41 (-1.15), NQ: 6.88 (-0.29), RGC: 21.82 (-0.08), MS: 34.66 (-0.05), MSG: 74.91 (-0.35), NVAX: 5.55 (+0.03), CQB: 14.41 (-0.02), SRPT: 16.38 (-0.02), RCPT: 104.00 (+0.69), TWTR: 40.90 (+0.69), PTIE: 1.73 (-0.05)
Health Care Stocks On The Rise With Help From 3 Stocks
at The Street - Tue Oct 28, 12:04PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
AMGN: 160.41 (-1.15), RCPT: 104.00 (+0.69), NVS: 91.93 (+0.23)
Receptos Soars After Lead Drug Racks Up Another Win
at Investor's Business Daily - Tue Oct 28, 10:46AM CDT
Receptos (RCPT) stock jumped more than 47% to a new high above 99 in morning trading on the stock market today, and the company got multiple price-target increases after its bowel-disease drug succeeded in a midstage trial. Receptos announced late...
JNJ: 108.62 (+1.16), RCPT: 104.00 (+0.69), ABBV: 62.66 (-0.59)
Stock Futures Positive, Steady; Vasco Rockets, Twitter Fades
at Investor's Business Daily - Tue Oct 28, 8:01AM CDT
Stock futures rolled up moderate gains ahead of Tuesday's open, as investors geared up for a session with many moving parts. Dow futures were steady, trading 73.1 points above fair market value. Nasdaq 100 futures were up a strong 19.4 points, and...
WHR: 172.72 (+0.12), VDSI: 25.80 (+0.32), RCPT: 104.00 (+0.69), BP: 41.65 (-0.81), TWTR: 40.90 (+0.69), AET: 83.71 (+1.46)
RECEPTOS
at Investor's Business Daily - Mon Oct 27, 5:48PM CDT
RECEPTOS (RCPT), a biotech, reported positive phase 2 trial results for its RPC1063 treatment for ulcerative colitis. Shares shot up 25.1% to 85.02.
RCPT: 104.00 (+0.69)
Receptos Reports Positive Phase 2 Results for TOUCHSTONE Trial of RPC1063 in Ulcerative Colitis
GlobeNewswire - Mon Oct 27, 3:01PM CDT
- Study met primary efficacy and all secondary endpoints with statistical significance for patients on 1 mg dose after 8 weeks of treatment -
RCPT: 104.00 (+0.69)
Surprising Stocks That Performed Best for Billionaires in 2014
at The Street - Mon Oct 27, 7:48AM CDT
See the stocks that have performed the best for 19 billionaires who made their money investing.
BDSI: 17.37 (-0.28), ATHL: 58.15 (+0.02), VIPS: 23.67 (+0.81), ARII: 63.49 (-2.19), SBAC: 110.69 (-1.64), BIOF: 7.28 (+0.01), BKW: 32.19 (-0.11), LUV: 36.43 (+1.12), HCA: 69.34 (-0.89), LPDX: 5.22 (unch), DTV: 87.43 (+0.15), RCPT: 104.00 (+0.69), WMB: 54.17 (-1.51), BRK.B: 142.18 (+1.37), BRK.A: 213,000.00 (+1,900.00), SBGL: 7.23 (-0.23), AN: 55.96 (-0.44)
Receptos Announces First Patient Treated With Anti-Interleukin-13 Antibody in Phase 2 Trial for Eosinophilic Esophagitis
GlobeNewswire - Fri Oct 03, 6:59AM CDT
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that the first patient has been treated in a Phase 2 trial of RPC4046, Receptos' development candidate for eosinophilic esophagitis (EoE). RPC4046 is a humanized monoclonal antibody directed against interleukin-13 (IL-13), a target which has been validated in other related allergic indications.
RCPT: 104.00 (+0.69)
The 5 Best Biotech Stocks in 2014...so far
Todd Campbell, The Motley Fool - Motley Fool - Fri Sep 26, 7:35AM CDT
Since the quarter is wrapping up and investors are considering their game plan heading into year-end, let's look at biotech's biggest winners for the year, why they've rallied, and whether they make sense for your portfolio . Specifically, let's...
GILD: 109.72 (-0.26), ACHN: 10.23 (-1.89), RCPT: 104.00 (+0.69), PTCT: 40.82 (-0.50), ICPT: 260.85 (+4.29), PBYI: 239.82 (-8.64)
Critical Alerts For FuelCell Energy, Receptos Inc., HD Supply Holdings Inc., Westport Innovations and Organovo Released By InvestorsObserver
PR Newswire - Thu Sep 11, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FCEL, RCPT, HDS, WPRT and ONVO.
WPRT: 5.82 (-0.15), FCEL: 2.13 (-0.06), ONVO: 7.13 (+0.43), HDS: 28.78 (+0.04), RCPT: 104.00 (+0.69)
Market Maker Surveillance Report. NPSP, CYTK, JDSU, INVT, MNDL, RCPT, Winning Stocks With Lowest Price Friction For Wednesday, September 10th 2014
M2 - Thu Sep 11, 4:12AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4911 companies with "abnormal" market making, 2481 companies with positive Friction Factors and 2383 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Wednesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. NPS Pharmaceuticals Inc (NASDAQ:NPSP), Cytokinetics Inc (NASDAQ:CYTK), JDS UNIPHASE CORPORATION (NASDAQ:JDSU), INVESTAMERICA INC (OTC:INVT), Mandalay Digital Group Inc (OTC:MNDL), (NASDAQ:RCPT). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
CYTK: 4.30 (+0.60), INVT: 1.33 (+0.02), RCPT: 104.00 (+0.69), JDSU: 13.47 (-0.11), NPSP: 27.18 (-0.11), MNDL: 3.54 (-0.21)
Good news for Receptos drug
at Investor's Business Daily - Wed Sep 10, 5:53PM CDT
The biotech's drug candidate RPC1063 reduces multiple-sclerosis relapses equally well as Novartis' (NVS) Gilenya, but with less risk of liver damage, according to results from a midstage clinical trial. Receptos (RCPT) already revealed its initial...
RCPT: 104.00 (+0.69), NVS: 91.93 (+0.23)
Receptos posts 3Q loss
Automated Insights - Tue Nov 04, 7:19AM CST
SAN DIEGO (AP) _ Receptos Inc. (RCPT) on Tuesday reported a loss of $32.2 million in its third quarter.
RCPT: 104.00 (+0.69)
Receptos Provides Development Updates and Reports Third Quarter 2014 Financial Results
GlobeNewswire - Tue Nov 04, 6:00AM CST
- Recent positive Phase 2 induction results for TOUCHSTONE trial of RPC1063 in ulcerative colitis (UC) support initiation of broad program in inflammatory bowel disease -
RCPT: 104.00 (+0.69)
Receptos to Present at Nomura BioPharma Conference
GlobeNewswire - Mon Nov 03, 3:01PM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that Faheem Hasnain, its President and Chief Executive Officer, will be presenting at the Nomura BioPharma Conference at the Mandarin Oriental Hotel in Boston. The presentation is scheduled for Thursday, November 6 at 2:15pm Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's website at www.receptos.com. A replay will be available for 14 days after the event.
RCPT: 104.00 (+0.69)
Clinical Trial Results, Product Approval Letter, Financial Results, and Upcoming Event - Research Reports on Receptos, Wright, United Therapeutics, Abbott and CareFusion
PR Newswire - Fri Oct 31, 7:40AM CDT
Today, Analysts Review released its research reports regarding Receptos Inc. (NASDAQ: RCPT), Wright Medical Group Inc. (NASDAQ: WMGI), United Therapeutics Corporation (NASDAQ: UTHR), Abbott Laboratories (NYSE: ABT) and CareFusion Corporation (NYSE: CFN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7594-100free.
ABT: 43.61 (+0.32), WMGI: 29.96 (-0.65), CFN: 57.38 (+0.13), UTHR: 124.81 (-5.61), RCPT: 104.00 (+0.69), WMGIZ: 4.40 (+0.20)
Receptos to Hold Third Quarter 2014 Financial Results Conference Call and Webcast
GlobeNewswire - Wed Oct 29, 3:12PM CDT
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, will announce financial results for the third quarter ended September 30, 2014 on Tuesday, November 4 before the markets open. The announcement will be followed by a live webcast and conference call at 8:00 a.m. Eastern time (5:00 a.m. Pacific time).
RCPT: 104.00 (+0.69)
Receptos (RCPT) Worth Watching: Stock Moves Up 41.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 8:39AM CDT
Receptos, Inc. (RCPT) was a big mover last session, as its shares rose over 41% on the day.
LCI: 56.25 (-1.27), PTLA: 27.89 (-0.29), RCPT: 104.00 (+0.69), IG: 9.95 (-0.10)
Nasdaq stocks posting largest percentage increases
AP - Tue Oct 28, 5:14PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
VDSI: 25.80 (+0.32), ECHO: 26.91 (+0.69), LAYN: 7.37 (+0.17), NVAX: 5.55 (+0.03), SCYX: 8.60 (-0.13), RCPT: 104.00 (+0.69), TRNX: 26.34 (-0.56), IDTI: 16.51 (+0.02), SANM: 25.22 (+0.10)
Twitter and Amgen are big market movers
AP - Tue Oct 28, 3:42PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
AMKR: 6.32 (-0.21), KSS: 55.17 (+0.22), MU: 33.37 (-0.14), PFE: 30.28 (+0.09), HAL: 51.18 (-2.70), AMGN: 160.41 (-1.15), NQ: 6.88 (-0.29), RGC: 21.82 (-0.08), MS: 34.66 (-0.05), MSG: 74.91 (-0.35), NVAX: 5.55 (+0.03), CQB: 14.41 (-0.02), SRPT: 16.38 (-0.02), RCPT: 104.00 (+0.69), TWTR: 40.90 (+0.69), PTIE: 1.73 (-0.05)
Health Care Stocks On The Rise With Help From 3 Stocks
at The Street - Tue Oct 28, 12:04PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
AMGN: 160.41 (-1.15), RCPT: 104.00 (+0.69), NVS: 91.93 (+0.23)
Receptos Soars After Lead Drug Racks Up Another Win
at Investor's Business Daily - Tue Oct 28, 10:46AM CDT
Receptos (RCPT) stock jumped more than 47% to a new high above 99 in morning trading on the stock market today, and the company got multiple price-target increases after its bowel-disease drug succeeded in a midstage trial. Receptos announced late...
JNJ: 108.62 (+1.16), RCPT: 104.00 (+0.69), ABBV: 62.66 (-0.59)
Stock Futures Positive, Steady; Vasco Rockets, Twitter Fades
at Investor's Business Daily - Tue Oct 28, 8:01AM CDT
Stock futures rolled up moderate gains ahead of Tuesday's open, as investors geared up for a session with many moving parts. Dow futures were steady, trading 73.1 points above fair market value. Nasdaq 100 futures were up a strong 19.4 points, and...
WHR: 172.72 (+0.12), VDSI: 25.80 (+0.32), RCPT: 104.00 (+0.69), BP: 41.65 (-0.81), TWTR: 40.90 (+0.69), AET: 83.71 (+1.46)
RECEPTOS
at Investor's Business Daily - Mon Oct 27, 5:48PM CDT
RECEPTOS (RCPT), a biotech, reported positive phase 2 trial results for its RPC1063 treatment for ulcerative colitis. Shares shot up 25.1% to 85.02.
RCPT: 104.00 (+0.69)
Receptos Reports Positive Phase 2 Results for TOUCHSTONE Trial of RPC1063 in Ulcerative Colitis
GlobeNewswire - Mon Oct 27, 3:01PM CDT
- Study met primary efficacy and all secondary endpoints with statistical significance for patients on 1 mg dose after 8 weeks of treatment -
RCPT: 104.00 (+0.69)
Surprising Stocks That Performed Best for Billionaires in 2014
at The Street - Mon Oct 27, 7:48AM CDT
See the stocks that have performed the best for 19 billionaires who made their money investing.
BDSI: 17.37 (-0.28), ATHL: 58.15 (+0.02), VIPS: 23.67 (+0.81), ARII: 63.49 (-2.19), SBAC: 110.69 (-1.64), BIOF: 7.28 (+0.01), BKW: 32.19 (-0.11), LUV: 36.43 (+1.12), HCA: 69.34 (-0.89), LPDX: 5.22 (unch), DTV: 87.43 (+0.15), RCPT: 104.00 (+0.69), WMB: 54.17 (-1.51), BRK.B: 142.18 (+1.37), BRK.A: 213,000.00 (+1,900.00), SBGL: 7.23 (-0.23), AN: 55.96 (-0.44)
Receptos Announces First Patient Treated With Anti-Interleukin-13 Antibody in Phase 2 Trial for Eosinophilic Esophagitis
GlobeNewswire - Fri Oct 03, 6:59AM CDT
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that the first patient has been treated in a Phase 2 trial of RPC4046, Receptos' development candidate for eosinophilic esophagitis (EoE). RPC4046 is a humanized monoclonal antibody directed against interleukin-13 (IL-13), a target which has been validated in other related allergic indications.
RCPT: 104.00 (+0.69)
The 5 Best Biotech Stocks in 2014...so far
Todd Campbell, The Motley Fool - Motley Fool - Fri Sep 26, 7:35AM CDT
Since the quarter is wrapping up and investors are considering their game plan heading into year-end, let's look at biotech's biggest winners for the year, why they've rallied, and whether they make sense for your portfolio . Specifically, let's...
GILD: 109.72 (-0.26), ACHN: 10.23 (-1.89), RCPT: 104.00 (+0.69), PTCT: 40.82 (-0.50), ICPT: 260.85 (+4.29), PBYI: 239.82 (-8.64)
Critical Alerts For FuelCell Energy, Receptos Inc., HD Supply Holdings Inc., Westport Innovations and Organovo Released By InvestorsObserver
PR Newswire - Thu Sep 11, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FCEL, RCPT, HDS, WPRT and ONVO.
WPRT: 5.82 (-0.15), FCEL: 2.13 (-0.06), ONVO: 7.13 (+0.43), HDS: 28.78 (+0.04), RCPT: 104.00 (+0.69)
Market Maker Surveillance Report. NPSP, CYTK, JDSU, INVT, MNDL, RCPT, Winning Stocks With Lowest Price Friction For Wednesday, September 10th 2014
M2 - Thu Sep 11, 4:12AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4911 companies with "abnormal" market making, 2481 companies with positive Friction Factors and 2383 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Wednesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. NPS Pharmaceuticals Inc (NASDAQ:NPSP), Cytokinetics Inc (NASDAQ:CYTK), JDS UNIPHASE CORPORATION (NASDAQ:JDSU), INVESTAMERICA INC (OTC:INVT), Mandalay Digital Group Inc (OTC:MNDL), (NASDAQ:RCPT). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
CYTK: 4.30 (+0.60), INVT: 1.33 (+0.02), RCPT: 104.00 (+0.69), JDSU: 13.47 (-0.11), NPSP: 27.18 (-0.11), MNDL: 3.54 (-0.21)
Good news for Receptos drug
at Investor's Business Daily - Wed Sep 10, 5:53PM CDT
The biotech's drug candidate RPC1063 reduces multiple-sclerosis relapses equally well as Novartis' (NVS) Gilenya, but with less risk of liver damage, according to results from a midstage clinical trial. Receptos (RCPT) already revealed its initial...
RCPT: 104.00 (+0.69), NVS: 91.93 (+0.23)
